MedTrace Logo

Study of AV-1959D, an Amyloid Beta Vaccine

NCT05642429 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-03-27

No results posted yet for this study

Summary

Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).

Conditions

  • Alzheimer Disease

Interventions

BIOLOGICAL

AV-1959D

Three doses of AV-1959D administered as a sterile suspension via intradermal injection

BIOLOGICAL

Placebo

Three doses of Placebo administered as a sterile suspension via intradermal injection

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Clinartis

    collaborator INDUSTRY

  • Institute for Molecular Medicine

    lead OTHER

Principal Investigators

  • Michael Agadjanyan, PhD · IMM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2026-07-20
Completion
2026-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642429 on ClinicalTrials.gov